ANSWER: C

Rationale:

ERα (encoded by ESR1) and ERβ (encoded by ESR2) share approximately 97% amino acid identity in the DNA-binding domain (DBD), reflecting strong conservation of the two zinc finger motifs that recognize estrogen response elements. By contrast, their ligand-binding domains (LBDs) share only about 59% identity. This divergence in the LBD is the structural basis for differential ligand-binding affinity between the two subtypes and is what makes it pharmacologically possible to design selective agonists and antagonists with tissue-selective profiles — the LBD is where the ligand binds and where the conformational change that determines coactivator recruitment is initiated.

• Option A: Option A is incorrect because it inverts the two homology values: the DBD is the highly conserved domain (~97%) and the LBD is the divergent domain (~59%); ligand selectivity arises from LBD divergence, not from differences in DNA-binding specificity.
• Option B: Option B is incorrect because the receptors are not nearly identical across all domains — the LBD divergence (~59%) is substantial and is precisely what permits receptor-level selectivity, so tissue selectivity does not depend entirely on coactivator expression.
• Option D: Option D is incorrect because the two receptors share substantial homology, particularly the highly conserved DBD (~97%); they are members of the same nuclear receptor subfamily and did not arise from entirely unrelated ancestral genes, and no SERM distinguishes the two subtypes in a fully complete manner.
• Option E: Option E is incorrect because ERα and ERβ do not share identical ligand-binding domains — the LBDs differ at ~59% identity; while AF-1 differences do contribute to functional divergence, the statement that the LBDs are identical is factually wrong and is the reason this option fails.

ANSWER: A

Rationale:

Tamoxifen acts as an estrogen receptor antagonist in breast tissue — the basis for its therapeutic effect in estrogen receptor-positive breast cancer — while acting as a partial agonist in bone and endometrium. The partial agonist activity in bone is favorable (it helps preserve bone mineral density), but the partial agonist activity in endometrium is clinically problematic because it stimulates endometrial proliferation and is associated with an increased risk of endometrial hyperplasia and endometrial cancer. This tissue-selective behavior is the defining pharmacological feature of SERMs and arises from the specific conformational change tamoxifen induces in the ER ligand-binding domain, which determines which coactivator or corepressor complexes are recruited in each tissue context.

• Option B: Option B is incorrect because it inverts tamoxifen's breast and bone activities: tamoxifen is an antagonist (not agonist) in breast and a partial agonist (not antagonist) in bone; it does not stimulate breast tumor growth.
• Option C: Option C is incorrect because tamoxifen is not a pure antagonist in all tissues — it has partial agonist activity in bone and endometrium, which is why it does not cause uniform bone loss and why it carries endometrial risk.
• Option D: Option D is incorrect because tamoxifen is an antagonist in breast (not a partial agonist) and a partial agonist in endometrium (not a pure antagonist); it increases rather than reduces endometrial cancer risk.
• Option E: Option E is incorrect because it reverses every tissue assignment: tamoxifen is an antagonist in breast and a partial agonist in bone and endometrium, so it does not worsen osteoporosis and does not act as a breast agonist.

ANSWER: D

Rationale:

Raloxifene acts as an estrogen receptor antagonist in both breast and endometrium while retaining agonist activity in bone. This profile is clinically important because, unlike tamoxifen — which is a partial agonist in the endometrium and therefore increases endometrial hyperplasia and endometrial cancer risk — raloxifene's endometrial antagonism means it does not carry the increased endometrial cancer risk. Both agents retain favorable bone agonist activity, which is why raloxifene is approved for osteoporosis prevention and treatment in postmenopausal women and also reduces the risk of invasive estrogen receptor-positive breast cancer. The difference in endometrial activity is the key discriminator between the two SERMs.

• Option A: Option A is incorrect because raloxifene is an antagonist (not agonist) in breast, and tamoxifen is not an antagonist in all three tissues — tamoxifen is a partial agonist in bone and endometrium.
• Option B: Option B is incorrect because raloxifene is an agonist (not antagonist) in bone and an antagonist (not agonist) in breast and endometrium; the option reverses raloxifene's actual profile.
• Option C: Option C is incorrect because raloxifene and tamoxifen do not have identical tissue-selective profiles — they differ specifically in endometrial activity (tamoxifen partial agonist vs raloxifene antagonist), which is the clinically decisive distinction, not merely a potency difference.
• Option E: Option E is incorrect because neither agent is a pure agonist or pure antagonist across all tissues — both are tissue-selective modulators; raloxifene has bone agonism with breast/endometrial antagonism, and tamoxifen has breast antagonism with bone/endometrial partial agonism.

ANSWER: B

Rationale:

Rapid non-genomic estrogen signaling occurs through a membrane-associated pool of estrogen receptor and through the G protein-coupled estrogen receptor (GPER), formerly known as GPR30. Unlike the classical genomic pathway — which requires receptor dimerization, DNA binding, transcription, and translation and therefore operates on a timescale of hours — GPER signaling produces effects within seconds to minutes. These rapid effects include activation of adenylyl cyclase, phospholipase C, and the MAPK and PI3K–Akt pathways, and importantly the activation of endothelial nitric oxide synthase (eNOS), which produces vasodilation. This rapid eNOS-mediated vasodilation partially explains the cardiovascular protection observed with estrogen in young premenopausal women.

• Option A: Option A is incorrect because nuclear ERα-mediated transcription requires messenger RNA synthesis and protein translation and therefore cannot produce effects within seconds; the rapid effects are non-genomic and membrane-initiated, not transcriptional.
• Option C: Option C is incorrect because ERβ binding to estrogen response elements in DNA is a genomic mechanism operating over hours, not a rapid non-genomic mechanism operating within seconds; DNA-binding transcriptional activity cannot account for second-to-minute responses.
• Option D: Option D is incorrect because the rapid vasoactive effects of estrogen are mediated by GPER and membrane ER, not by the progesterone receptor PR-B; furthermore, estrogen-mediated rapid signaling produces vasodilation (via eNOS), not vasoconstriction.
• Option E: Option E is incorrect because aromatase is a steroidogenic enzyme that converts androgens to estrogens, not a signaling receptor; it does not mediate rapid membrane-initiated vasodilation, and its action is metabolic rather than a seconds-to-minutes signal transduction event.

ANSWER: E

Rationale:

The rate-limiting step in steroidogenesis is the translocation of cholesterol from the outer to the inner mitochondrial membrane, mediated by the steroidogenic acute regulatory protein (StAR). Cholesterol delivery to the inner mitochondrial membrane — where the cytochrome P450 side-chain cleavage enzyme (CYP11A1) resides — is the bottleneck of the entire pathway. LH acutely regulates steroidogenesis precisely at this step: LH binding to its Gs-coupled receptor raises cyclic AMP, activates protein kinase A (PKA), and PKA phosphorylates StAR, increasing cholesterol translocation and thereby increasing the substrate available for the downstream enzymatic cascade. This is why StAR is the principal site of acute (minutes-to-hours) hormonal regulation of steroid output.

• Option A: Option A is incorrect because aromatization by CYP19A1 occurs in the granulosa cell (not the theca cell) and is not the rate-limiting step of the overall steroidogenic pathway; it is a regulated step for estrogen production but not the classical rate-limiting bottleneck.
• Option B: Option B is incorrect because the conversion of pregnenolone to progesterone by 3β-HSD is not the rate-limiting step; while 3β-HSD does use NAD+ as a cofactor, cofactor availability is not the bottleneck that defines the rate-limiting step of steroidogenesis.
• Option C: Option C is incorrect because the lyase activity of CYP17A1 is an important branch-point reaction but is not the classical rate-limiting step; the acute regulation of steroid output is exerted at the StAR-mediated cholesterol translocation step, not at the CYP17A1 lyase reaction.
• Option D: Option D is incorrect because, although CYP11A1 (side-chain cleavage) catalyzes the first committed enzymatic conversion (cholesterol to pregnenolone), the true rate-limiting step is the delivery of cholesterol substrate to CYP11A1 via StAR-mediated translocation; CYP11A1 is not saturated and rate-limited under basal conditions in the way described, and acute regulation acts on substrate delivery rather than on CYP11A1 itself.

ANSWER: A

Rationale:

Estradiol (E2) is the most potent of the three naturally occurring estrogens, with a relative binding affinity for ERα approximately ten-fold greater than estrone (E1). Estradiol is produced primarily by the ovary during the reproductive years and is the principal secretory product of the preovulatory follicle. Estrone is produced mainly by peripheral aromatization of adrenal androstenedione in adipose tissue and becomes the dominant circulating estrogen after menopause when ovarian production ceases. Estriol (E3) is a weak estrogen produced in large quantities by the placenta during pregnancy through fetal adrenal and hepatic metabolism of dehydroepiandrosterone sulfate (DHEA-S); its low systemic potency is clinically exploited in local vaginal preparations.

• Option B: Option B is incorrect because estrone is not the most potent estrogen and is not the primary ovarian secretory product during reproductive years; estradiol is both the most potent and the principal ovarian estrogen, and estrone becomes dominant only after menopause.
• Option C: Option C is incorrect because estriol is the weakest of the three estrogens, not the most potent, and it is not the primary product of the preovulatory follicle; estradiol is the most potent and the principal follicular estrogen.
• Option D: Option D is incorrect because the three estrogens do not have equal binding affinity for ERα — estradiol has approximately ten-fold greater affinity than estrone, and estriol is weaker still; the potency differences are driven by receptor affinity, not solely by plasma protein binding.
• Option E: Option E is incorrect because estradiol and estriol do not have equal potency — estradiol is far more potent than estriol — and estrone is not exclusively a placental estrogen; estrone is produced by peripheral aromatization in adipose tissue and is the dominant estrogen after menopause in non-pregnant women.

ANSWER: C

Rationale:

Oral natural estradiol has a bioavailability of only approximately 5% because it undergoes extensive first-pass conversion to estrone and estrone conjugates by 17β-hydroxysteroid dehydrogenase in the intestinal mucosa and liver. Ethinyl estradiol, by contrast, has an oral bioavailability of approximately 40–45% because the 17α-ethynyl group prevents oxidative metabolism at the C-17 position by CYP3A4 — the reaction that otherwise rapidly inactivates natural estradiol. This structural protection against first-pass degradation is the specific reason EE was developed for oral contraceptive use, where reliable oral bioavailability is essential. Note that EE bioavailability is still highly variable across individuals (range 20–65%) due in part to polymorphisms in intestinal CYP3A4 expression.

• Option A: Option A is incorrect because it inverts the two bioavailability values: estradiol is ~5% and EE is ~40–45%, not the reverse; and the reason EE has higher bioavailability is its resistance to oxidation, not greater conjugation.
• Option B: Option B is incorrect because oral estradiol and EE do not have the same bioavailability — estradiol (~5%) is far lower than EE (~40–45%); the difference is a genuine bioavailability difference driven by first-pass metabolism, not merely a potency difference.
• Option D: Option D is incorrect because oral estradiol does not have ~90% bioavailability — it is approximately 5% due to extensive first-pass metabolism; estradiol is not actively transported in a way that overcomes first-pass inactivation.
• Option E: Option E is incorrect because EE does not have a bioavailability below 10% — it is approximately 40–45%; combined oral contraceptives use low EE doses (20–35 micrograms) precisely because EE's good oral bioavailability and resistance to inactivation make high doses unnecessary.

ANSWER: B

Rationale:

Conjugated equine estrogens (CEE, brand name Premarin) are extracted from the urine of pregnant mares and consist of a complex mixture of water-soluble estrogen sulfates. The major components are sodium estrone sulfate (approximately 50–60%) and sodium equilin sulfate (approximately 22–30%), with smaller amounts of 17α-dihydroequilin, 17β-dihydroequilin, equilenin, and delta-8,9-dehydroestrone sulfate. The equine estrogens equilin and equilenin are not present in human physiology and have binding affinities for ERα comparable to estradiol but considerably longer half-lives because they resist conversion to inactive metabolites by human hepatic enzymes. This composition is the basis for the pharmacological distinctiveness of CEE relative to estradiol-based preparations.

• Option A: Option A is incorrect because CEE does not contain ethinyl estradiol — EE is a synthetic compound used in oral contraceptives, whereas CEE is a urine-derived mixture of conjugated estrone and equine estrogen sulfates.
• Option C: Option C is incorrect because CEE is not predominantly unconjugated estradiol-17β and does not mirror the human ovarian estrogen profile; it is a sulfate-conjugated mixture rich in estrone sulfate and equine estrogens not found in humans.
• Option D: Option D is incorrect because CEE contains estrogens, not progestins; micronized progesterone and medroxyprogesterone acetate are progestins that may be co-prescribed with CEE for endometrial protection but are not components of CEE itself.
• Option E: Option E is incorrect because CEE is not an equal-parts mixture of the three human estrogens in free form; it is dominated by estrone sulfate and equilin sulfate in conjugated form and contains equine-specific estrogens absent from human physiology.

ANSWER: D

Rationale:

Crystalline progesterone has very poor oral bioavailability (less than 10%) with highly variable peak plasma levels because of rapid first-pass metabolism. Micronization reduces the progesterone particle size to approximately 10–50 microns and suspends the drug in oil-filled capsules (brand names Prometrium and Utrogestan), which substantially improves dissolution and absorption and raises oral bioavailability to approximately 10–15%. This improvement is sufficient for clinical indications such as endometrial protection in hormone therapy and luteal phase support in assisted reproduction. Micronized progesterone is metabolized by CYP3A4 and 5α-reductase to allopregnanolone and pregnanolone, the neuroactive metabolites responsible for its characteristic sedative effects.

• Option A: Option A is incorrect because micronized progesterone is not a synthetic ester — it is bioidentical progesterone in a reduced particle size formulation; its bioavailability is approximately 10–15%, not 90%.
• Option B: Option B is incorrect because micronization is a physical particle-size reduction, not a chemical conversion to medroxyprogesterone acetate; MPA is a distinct synthetic progestin, not the product of micronizing progesterone.
• Option C: Option C is incorrect because micronized progesterone does not have bioavailability identical to crystalline progesterone — micronization meaningfully improves absorption from less than 10% to approximately 10–15%; the change is a true particle-size reduction affecting dissolution and absorption, not merely a tablet coating change.
• Option E: Option E is incorrect because micronized progesterone is not a prodrug activated by intestinal esterases, does not achieve approximately 50% bioavailability, and does not avoid first-pass metabolism entirely; it undergoes substantial first-pass metabolism, which is why its oral bioavailability remains modest at approximately 10–15%.

ANSWER: E

Rationale:

Drospirenone is a fourth-generation progestin uniquely derived from spironolactone (an aldosterone antagonist), and it possesses both anti-androgenic activity through androgen receptor (AR) antagonism and anti-mineralocorticoid activity through mineralocorticoid receptor (MR) antagonism. The anti-mineralocorticoid activity produces mild natriuresis and modest blood pressure lowering, which is the basis for its selection in premenstrual dysphoric disorder and in patients where the anti-androgenic and anti-mineralocorticoid profile is advantageous. This spironolactone-derived dual antagonist activity distinguishes drospirenone from all other progestin classes.

• Option A: Option A is incorrect because levonorgestrel is a second-generation 19-nortestosterone-derived progestin with high androgenic activity — it is not derived from spironolactone and does not have anti-mineralocorticoid activity; drospirenone, not levonorgestrel, is the spironolactone-derived agent used in PMDD.
• Option B: Option B is incorrect because medroxyprogesterone acetate is derived from 17α-hydroxyprogesterone (a first-generation progestin), not from 19-nortestosterone, and it does not have the highest androgenic index — among commonly used progestins, levonorgestrel has the highest androgenic index.
• Option C: Option C is incorrect because norethindrone is a first-generation 19-nortestosterone-derived progestin, not a fourth-generation spironolactone derivative, and it has androgenic rather than anti-androgenic activity; it is not preferentially used for hirsutism.
• Option D: Option D is incorrect because dienogest is a 19-nortestosterone-derived progestin with strong progesterone receptor agonism and anti-androgenic activity (not a first-generation 17α-hydroxyprogesterone derivative), and it does not have strong glucocorticoid activity; its use in endometriosis is based on its progestational and anti-androgenic properties, not glucocorticoid-mediated anti-inflammatory effects.

ANSWER: A

Rationale:

Levonorgestrel is highly protein-bound — approximately 50% to SHBG and approximately 47% to albumin — leaving a free (biologically active) fraction of only about 1–3%. Ethinyl estradiol is a potent inducer of hepatic SHBG production. When EE is present in a combined oral contraceptive, the rise in SHBG increases the proportion of levonorgestrel bound to SHBG, thereby reducing the free active fraction of levonorgestrel. This is one reason levonorgestrel dose requirements differ between combined preparations (where EE-induced SHBG lowers the free fraction) and progestin-only preparations (where no EE is present to induce SHBG). This is a foundational pharmacokinetic interaction within the combined pill itself.

• Option B: Option B is incorrect because EE induces (increases) rather than suppresses hepatic SHBG production; the direction of the effect is opposite to what this option states.
• Option C: Option C is incorrect because EE does affect SHBG — it is a potent SHBG inducer — and levonorgestrel binding is not determined entirely by albumin; approximately half of bound levonorgestrel is bound to SHBG, which is estrogen-responsive.
• Option D: Option D is incorrect because EE's effect on the free fraction of levonorgestrel operates through SHBG induction, not through albumin displacement; the SHBG increase reduces (not increases) the free fraction of levonorgestrel.
• Option E: Option E is incorrect because EE does not convert levonorgestrel to a more highly protein-bound metabolite; its effect is mediated by induction of SHBG synthesis, which alters the binding equilibrium of levonorgestrel itself, and dose differences between preparations are clinically relevant rather than eliminated.

ANSWER: C

Rationale:

Oral estradiol is absorbed into the portal circulation and delivered to the liver at high concentrations during first-pass, which strongly stimulates hepatic synthesis of sex hormone-binding globulin (SHBG), C-reactive protein (CRP), angiotensinogen, and coagulation factors (including factors VII, IX, X, and fibrinogen). Transdermal estradiol, by contrast, enters the systemic venous circulation directly through the skin and reaches the liver only at systemic plasma concentrations — bypassing the concentrated portal bolus — and therefore produces minimal increases in these hepatic proteins. This difference in hepatic protein stimulation is the mechanistic basis for the differing venous thromboembolism risk profiles of oral versus transdermal estrogen and is a foundational discriminator between the two routes.

• Option A: Option A is incorrect because it reverses the relationship: transdermal estradiol produces smaller, not greater, increases in hepatic proteins; skin absorption bypasses rather than concentrates hepatic delivery.
• Option B: Option B is incorrect because oral and transdermal estradiol do not produce identical hepatic responses — the route of absorption determines whether the liver is exposed to high portal concentrations (oral) or only systemic concentrations (transdermal).
• Option D: Option D is incorrect because neither route decreases coagulation factors or SHBG in the manner described; oral estradiol increases both coagulation factors and SHBG via portal first-pass, while transdermal produces minimal change — the two are not opposite mirror images.
• Option E: Option E is incorrect because estradiol does have hepatic estrogen receptor activity and does affect hepatic protein synthesis; the liver is a major ERα-expressing target tissue, which is precisely why the route of administration matters for hepatic protein responses.

ANSWER: B

Rationale:

Rifampin is the most potent CYP3A4 inducer encountered in clinical practice. It induces both CYP3A4 and CYP2C9, reducing ethinyl estradiol area under the curve (AUC) by greater than 50% and reducing progestin AUCs comparably, with induction persisting for 4–6 weeks after cessation. Rifabutin is also a CYP3A4 inducer but is weaker than rifampin; its interaction with hormonal contraceptives is clinically relevant but less pronounced, and the certainty of clinically significant contraceptive failure is correspondingly lower, though backup or alternative contraception is still generally advised. The key discrimination is that rifampin is the strongest inducer of this class while rifabutin is a weaker inducer.

• Option A: Option A is incorrect because rifampin and rifabutin are not equally potent inducers — rifampin is substantially more potent than rifabutin, and the AUC reduction figure of greater than 80% overstates and incorrectly equates their effects.
• Option C: Option C is incorrect because it reverses the relative potency: rifampin, not rifabutin, is the more potent CYP3A4 inducer; rifabutin's effect is weaker.
• Option D: Option D is incorrect because rifampin does not inhibit CYP3A4 — both rifampin and rifabutin are inducers (rifampin strong, rifabutin weaker); they do not have opposite effects on EE levels.
• Option E: Option E is incorrect because, although rifamycins do target bacterial RNA polymerase for their antibacterial action, rifampin and rifabutin also induce human hepatic CYP3A4, and this induction is the well-established basis for their interaction with hormonal contraceptives.

ANSWER: D

Rationale:

Ethinyl estradiol potently induces UGT1A4 (uridine diphosphate-glucuronosyltransferase 1A4), the enzyme primarily responsible for glucuronidation and inactivation of lamotrigine. When a combined oral contraceptive containing EE is started in a woman stabilized on lamotrigine, lamotrigine plasma concentrations fall by approximately 40–65% within the first weeks, substantially increasing the risk of breakthrough seizures. The correct anticipatory management is therefore to plan for a likely increase in the lamotrigine dose at the time the combined pill is started — ideally coordinated with the prescribing neurologist — and to anticipate the need to reduce lamotrigine again if the pill is later stopped (because levels will rebound).

• Option A: Option A is incorrect because EE and lamotrigine do interact — EE induces UGT1A4, the major lamotrigine-metabolizing enzyme; they do not have entirely separate non-overlapping pathways.
• Option B: Option B is incorrect because EE induces (not inhibits) UGT1A4, which lowers rather than raises lamotrigine levels; reducing the lamotrigine dose at pill initiation would worsen the risk of breakthrough seizures.
• Option C: Option C is incorrect because the interaction is well-characterized and fully anticipatable; waiting for a breakthrough seizure before acting is inappropriate when proactive dose adjustment or a non-interacting contraceptive method can prevent it.
• Option E: Option E is incorrect because lamotrigine does not induce CYP3A4 and does not reduce EE efficacy; the interaction runs in the direction of EE lowering lamotrigine, not lamotrigine lowering EE, so doubling the EE dose is not the correct management.

ANSWER: E

Rationale:

The etonogestrel implant achieves initial serum concentrations of approximately 400–600 picograms per milliliter shortly after insertion. These levels decline over time to approximately 180–200 picograms per milliliter by year three. Critically, etonogestrel levels remain above the threshold required for ovulation suppression — approximately 90 picograms per milliliter — throughout the entire approved three-year duration, which is what allows the implant to maintain reliable contraceptive efficacy across its full lifespan. After implant removal, etonogestrel (metabolized by CYP3A4 with a terminal half-life of approximately 25 hours) clears within days, allowing return of ovulation within approximately 3–4 weeks.

• Option A: Option A is incorrect because etonogestrel levels do not remain constant at 90 picograms per milliliter; they start much higher (400–600) and decline to 180–200 by year three, remaining above the ovulation threshold rather than sitting exactly at it.
• Option B: Option B is incorrect because etonogestrel levels fall over time (from 400–600 down to 180–200), they do not rise progressively to 600 picograms per milliliter; the implant releases progressively less drug as it ages.
• Option C: Option C is incorrect because etonogestrel is released by steady controlled diffusion, not in a pulsatile pattern synchronized to the menstrual cycle; there are no engineered mid-cycle peaks and menstrual troughs.
• Option D: Option D is incorrect because etonogestrel levels remain above the ovulation suppression threshold throughout the three-year duration; they do not fall below the threshold within the first year, and ovulation suppression — not cervical mucus thickening alone — remains a primary mechanism throughout.

ANSWER: B

Rationale:

The NNRTI class is heterogeneous in its interactions with hormonal contraceptives. Efavirenz and nevirapine are potent CYP3A4 inducers that substantially reduce ethinyl estradiol and progestin plasma levels and are associated with increased risk of contraceptive failure. Etravirine is a moderate inducer with an intermediate, clinically relevant interaction. Rilpivirine does not induce CYP3A4 and does not impair contraceptive efficacy, making it the NNRTI with a neutral interaction profile. This within-class heterogeneity is the key discrimination: the choice of specific NNRTI determines whether a contraceptive interaction exists.

• Option A: Option A is incorrect because not all NNRTIs are potent inducers — rilpivirine is contraceptive-neutral, and etravirine is only a moderate inducer; a copper IUD is not the only option across the entire class.
• Option C: Option C is incorrect because NNRTIs in this class are inducers (efavirenz, nevirapine) or neutral (rilpivirine), not CYP3A4 inhibitors that raise EE levels; the premise of estrogen toxicity from NNRTI-mediated inhibition is incorrect.
• Option D: Option D is incorrect because it inverts the actual profile: rilpivirine is the contraceptive-neutral NNRTI, while efavirenz and nevirapine are the potent inducers that reduce EE levels; efavirenz and nevirapine are not contraceptive-neutral.
• Option E: Option E is incorrect because efavirenz and nevirapine induce (and thereby lower) rather than inhibit (and raise) EE levels, and rilpivirine is neutral rather than an inducer; the directions of effect stated in this option are wrong.